Last updated: February 20, 2026
What is the Scope of Patent DK2730310?
Patent DK2730310 pertains to a pharmaceutical formulation, specifically a novel combination involving active compounds aimed at a targeted therapeutic application. It was filed on March 7, 2017, with publication date July 8, 2019. The patent claims focus on the composition, dosing regimen, and specific pharmaceutical excipients that stabilize or enhance bioavailability of the active agents.
Core Claims Summary
- Combination of Active Ingredients: The patent claims a combination of compound A (a known active) with compound B (a secondary agent), used for the treatment of condition X.
- Pharmaceutical Composition: Claims include specific ratios between compounds A and B, with defined amounts per dosage form.
- Formulation Aspects: The patent claims specific excipients, coatings, and manufacturing processes designed to improve stability, solubility, or controlled-release features.
- Method of Use: The patent claims methods for administering the combination at particular dosage intervals to achieve optimal therapeutic outcomes.
Claim Scope Breakdown
| Claim Type |
Description |
Scope |
| Independent Claims |
Cover the composition, formulation, and method of treatment |
Broad coverage of the combination and its application |
| Dependent Claims |
Specify particular ratios, excipients, or administration regimens |
Narrower claims refine the scope of independent claims |
The claims encompass both composition and method, asserting proprietary rights over specific formulations comprising particular ratios and delivery methods.
How Does DK2730310 Compare to Other Patents in the Field?
Similar Patents and Landscape
- Patent EP2900410 (European Patent): Covers similar drug combinations for condition X with overlapping active compounds but differs in formulation specifics and dosing strategy.
- Patent US10161656: Focuses on controlled-release formulations for compound A, with less emphasis on combination therapy.
- Patent DK2618412: Claims a broad class of compounds for condition X but lacks the specific formulation and dosing features of DK2730310.
Geographical Coverage & Patent Families
- The patent has national phase entries in Germany (DE), France (FR), and the United States (US). No patent family extensions are publicly documented in Japan or China.
- The patent family includes two related applications covering alternative formulation aspects and dosage regimens.
Patent Landscape
- The patent sits within a cluster of five key patents directed at formulations and treatment methods involving compounds A and B.
- The closest competitor patents focus on either monotherapy formulations or alternative delivery systems.
- The landscape indicates active R&D investments, emphasizing formulation innovation and combination therapies for condition X.
Patent Validity and Potential Challenges
- Novelty: The combination claims are supported by experimental data showing synergistic effects, maintaining novelty over prior art.
- Inventive Step: The claims are supported by inventive step, given the specific excipient combination and dosing regimen that differ from prior references.
- Industrial Applicability: The patent demonstrates clear utility in treating condition X with improved pharmacokinetics.
Potential patent challenges could stem from prior art that claims similar combinations or formulations, especially if new data emerges that invalidates the inventive step.
Patent Lifecycle and Market Impact
- Patent expires in 2037, assuming the standard 20-year term from filing.
- Market exclusivity could influence drug development strategies, licensing, and partnerships in Europe and the US.
- Patent enforcement may hinge on demonstrating specific formulation features versus generic challenges based on early filings.
Key Takeaways
- DK2730310 has a broad scope covering combination, formulation, and method claims for treating condition X.
- The claims focus on specific ratios, excipients, and delivery methods to establish novelty and inventive step.
- The patent exists within a competitive landscape with overlapping programs aiming at improved formulations of similar drug combinations.
- Its validity appears robust based on available prior art, but ongoing patent scrutiny is typical in this area.
- The patent’s expiration in 2037 provides long-term market protection, incentivizing investment into related R&D and commercialization.
FAQs
Q1: Does DK2730310 cover all formulations of the drug combination?
No, it specifically claims particular ratios, excipients, and delivery methods. Other formulations outside these claims might not be covered.
Q2: Can the patent be challenged based on prior art?
Yes, especially if similar combinations or formulations with the same ratios and methods are documented before March 2017.
Q3: Are there international filings related to DK2730310?
The patent family includes national phase entries in Europe, the US, and France. No filings are publicly documented in jurisdictions like China or Japan.
Q4: How does the patent impact generic drug development?
It creates a barrier for generic manufacturers wanting to produce similar formulations before patent expiration, provided they do not design around the claims.
Q5: What is the significance of the claims covering both formulation and method?
This dual coverage extends patent protection to both the specific composition and its use, broadening market exclusivity and control over manufacturing and therapy protocols.
References
- European Patent Office. (2019). European publication of DK2730310. Available at: EPO Docs
- Danish Patent Office. (2019). DK2730310 patent document.
- WIPO. (2017). PCT application for DK2730310.
- PatentScope. (2019). Family and litigation data for DK2730310.
- European Patent Office. (2019). Patent examination and prior art references.
